STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.53
-$0.12 (-1.80%)
At close: Oct 30, 2026, 3:59 PM ET
$6.41
-$0.12 (-1.84%)
Pre-market:
Nov 2, 2026, 4:48 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 |
|---|---|
Net Income | -60.61M |
Depreciation & Amortization | 6.94M |
Stock-Based Compensation | 4.55M |
Other Working Capital | 1.11M |
Other Non-Cash Items | 23.23M |
Deferred Income Tax | -32K |
Change in Working Capital | 1.33M |
Operating Cash Flow | -24.59M |
Capital Expenditures | -3.2M |
Cash Acquisitions | n/a |
Purchase of Investments | n/a |
Sales Maturities Of Investments | n/a |
Other Investing Acitivies | 126K |
Investing Cash Flow | -3.07M |
Debt Repayment | -20.04M |
Common Stock Repurchased | n/a |
Dividend Paid | n/a |
Other Financial Acitivies | -1.04M |
Financial Cash Flow | 11.56M |
Net Cash Flow | -16.1M |
Free Cash Flow | -27.79M |
Adj. Free Cash Flow | -32.34M |
Maintenance CapEx | -3.2M |
Growth CapEx | n/a |
Owner Earnings | -27.79M |
Add to Watchlist
Select watchlists to add or remove STLN